Who Is Gilead's Competitors
Final Paper: Gilead Sciences Inc.
Our company, Gilead Sciences is a leading biopharmaceutical company that discovers, develops, and commercializes therapeutics. Currently, Gilead is a publicly traded company and a member of the NASDAQ Biotechnology Index and the S&P 500. Our company currently has a portfolio of 15 marketed products as well as a growing pipeline of investigational drugs focusing on HIV/AIDS, hepatitis, serious respiratory, cardiovascular, metabolic conditions, cancer, and inflammation. Over the past decade , we have been a strong competitor in the market up until this past year.
During the past 12 months, our stock prices have fluctuated quite a bit with a 52 week low of $36.98 and a 52 week …show more content…
Since our founding, Gilead Sciences has followed a business strategy of differentiation in a focused market. We have also been dependent on our “first-mover advantage” to enable us to discover and patent the best drugs in the market, so that buyer power is almost significantly eliminated. Yet, now many of our investors are beginning to wonder if Gilead can continue to innovate and survive against the upcoming threats of new branded competitors, major patent expirations, and increased pricing …show more content…
Stock Information taken from MarketWatch (http://www.marketwatch.com/investing/stock/gild)
3. Samaha, Lee. "Earnings View." : Gilead Facing Challenges. N.p., n.d. Web. 06 Dec. 2012.< http://earningsview.blogspot.com/2011/01/gilead-facing-challenges.html>
Gilead Facing Challenges
“It has been a difficult couple of years for investors in the stock of Gilead Sciences and, they could be forgiven for thinking that more headwinds are coming in 2011. A number of well documented issues have challenged the biotech and pharmaceutical industry. Firstly, US Health care reforms have hurt sales, put pricing under pressure and an increasing amount of the cost increases are becoming less tax deductible. Secondly, increasing patent expires are challenging the incumbent suppliers, Finally, European medical authorities are putting increasing pressure on prices.
Furthermore, Gilead has its own specific issues. One of the key drugs in its anti-HIV franchise (Viread) will see its patent run out in 2017. Viread made up 10% of product sales revenues in 2010. Gilead has been hit with pressure on HIV funding in the US and this could replicated worldwide.
However, as all good investors should ask themselves, is it already in the
Our company, Gilead Sciences is a leading biopharmaceutical company that discovers, develops, and commercializes therapeutics. Currently, Gilead is a publicly traded company and a member of the NASDAQ Biotechnology Index and the S&P 500. Our company currently has a portfolio of 15 marketed products as well as a growing pipeline of investigational drugs focusing on HIV/AIDS, hepatitis, serious respiratory, cardiovascular, metabolic conditions, cancer, and inflammation. Over the past decade , we have been a strong competitor in the market up until this past year.
During the past 12 months, our stock prices have fluctuated quite a bit with a 52 week low of $36.98 and a 52 week …show more content…
Since our founding, Gilead Sciences has followed a business strategy of differentiation in a focused market. We have also been dependent on our “first-mover advantage” to enable us to discover and patent the best drugs in the market, so that buyer power is almost significantly eliminated. Yet, now many of our investors are beginning to wonder if Gilead can continue to innovate and survive against the upcoming threats of new branded competitors, major patent expirations, and increased pricing …show more content…
Stock Information taken from MarketWatch (http://www.marketwatch.com/investing/stock/gild)
3. Samaha, Lee. "Earnings View." : Gilead Facing Challenges. N.p., n.d. Web. 06 Dec. 2012.< http://earningsview.blogspot.com/2011/01/gilead-facing-challenges.html>
Gilead Facing Challenges
“It has been a difficult couple of years for investors in the stock of Gilead Sciences and, they could be forgiven for thinking that more headwinds are coming in 2011. A number of well documented issues have challenged the biotech and pharmaceutical industry. Firstly, US Health care reforms have hurt sales, put pricing under pressure and an increasing amount of the cost increases are becoming less tax deductible. Secondly, increasing patent expires are challenging the incumbent suppliers, Finally, European medical authorities are putting increasing pressure on prices.
Furthermore, Gilead has its own specific issues. One of the key drugs in its anti-HIV franchise (Viread) will see its patent run out in 2017. Viread made up 10% of product sales revenues in 2010. Gilead has been hit with pressure on HIV funding in the US and this could replicated worldwide.
However, as all good investors should ask themselves, is it already in the